Table of Contents

Preface —— V

List of contributing authors —— VII

Table of Contents —— XI

Introduction to Volume 1: Kallikrein-related Peptidases. Characterization, Regulation, and Interactions Within the Protease Web —— 1

Bibliography —— 3

1 **Genomic Structure of the *KLK* Locus —— 5**

1.1 Introduction —— 5

1.2 Kallikreins in rodents —— 6

1.2.1 The mouse kallikrein gene family —— 7

1.2.2 The rat kallikrein gene family —— 8

1.3 Characterization and sequence analysis of the human *KLK* gene locus —— 9

1.3.1 Locus overview —— 9

1.3.2 Repeat elements and pleomorphism —— 11

1.4 Structural features of the human *KLK* genes and proteins —— 12

1.4.1 Common structural features —— 12

1.5 Sequence variations of human *KLK* genes —— 13

1.6 Regulation of *KLK* activity —— 14

1.6.1 At the mRNA level —— 14

1.6.2 Locus control of *KLK* expression —— 15

1.6.3 Epigenetic regulation of *KLK* gene expression —— 17

1.7 Isoforms and splice variants of human *KLKs* —— 18

1.8 Evolution of *KLKs* —— 21

Bibliography —— 22

2 **Single Nucleotide Polymorphisms in the Human *KLK* Locus and Their Implication in Various Diseases —— 31**

2.1 Introduction —— 31

2.2 *KLK* SNPs – data-mining from SNPdb and 1000 Genomes —— 32

2.3 Functional annotations using web-based prediction tools —— 34

2.4 Experimentally validated functional *KLK* SNPs —— 35

2.5 *KLK* SNP haplotypes and tagging —— 36

2.6 Malignant and non-malignant diseases and association with *KLK* SNPs —— 38

2.6.1 Association studies on high-risk variants in *KLK* genes —— 39

2.6.2 Association studies on low-risk variants in *KLK* genes — 39
2.7 Conclusions — 71
Bibliography — 71

3 Evolution of Kallikrein-related Peptidases — 79
3.1 Introduction — 79
3.2 Basic elements of phylogenetic analysis — 80
3.3 Evolutionary trends at the KLK locus — 80
3.4 Evolution of the *KLK1–KLK4* sublocus — 82
3.4.1 *KLK2* and *KLK3* originate from a duplicated segment containing both *KLK1* and *KLK15* — 82
3.4.2 A large number of *KLK1* tandem repeats in the house mouse — 85
3.4.3 The rat *KLK1* sublocus consists of 10 large repeats — 87
3.4.4 Four duplications of *KLK1* and *KLK15* in the dog — 88
3.4.5 A large repeat containing *KLK4* in the horse — 90
3.5 *KLK* genes in non-mammalian species — 92
3.6 General conclusions and remarks on the evolution of KLK genes — 93
Bibliography — 94

4 Structural Aspects of Kallikrein-related Peptidases — 97
4.1 Introduction — 97
4.2 Individual KLK structures — 98
4.2.1 Tissue kallikrein (KLK1) — 98
4.2.2 Prostate specific antigen (PSA/KLK3) — 100
4.2.3 Prostase (KLK4) — 101
4.2.4 Stratum corneum tryptic enzyme (SCTE/KLK5) — 104
4.2.5 Myelencephalon-specific protease or neurosin (MSP/KLK6) — 106
4.2.6 Stratum corneum chymotryptic enzyme (SCCE/KLK7) — 108
4.2.7 Neuropsin (KLK8) — 110
4.2.8 Other mammalian KLK structures — 111
Bibliography — 112

5 Molecular Recognition Properties of Kallikrein-related Peptidases on Synthetic and Endogenous Substrates — 117
5.1 Introduction — 117
5.2 Substrate specificities of individual kallikrein-related peptidases — 121
5.2.1 The classical kallikreins (KLK1, KLK2, KLK3) — 121
5.2.2 KLK4/KLK5/KLK7 — 125
5.2.3 KLK6/KLK13/KLK14 — 127
5.2.4 KLK8/KLK10/KLK12 — 129

5.2.5 KLK9/KLK11/KLK15 — 130
Bibliography — 132

6 Natural, Engineered and Synthetic Inhibitors of Kallikrein-related Peptidases — 141
6.1 Introduction — 141
6.2 KLK diversity — 141
6.3 The KLK superfamily: Structure and catalytic mechanism — 141
6.4 KLK inhibition: Rationale and mechanisms — 143
6.5 Proteinaceous inhibitors — 144
6.5.1 Kunitz domain inhibitors — 144
6.5.2 Kazal domain inhibitors — 146
6.5.3 Other canonical inhibitors — 147
6.5.4 Serpins — 147
6.6 Naturally occurring small molecule kallikrein inhibitors — 148
6.7 Engineered KLK Inhibitors — 149
6.7.1 Approaches to inhibitor design — 150
6.7.2 Pharmacological challenges for therapeutic inhibitors — 150
6.7.3 Serpins — 150
6.7.4 Ecotin — 151
6.7.5 Sunflower Trypsin Inhibitor (SFTI) — 152
6.7.6 Warhead inhibitors — 153
6.8 Conclusions and outlook — 154
Acknowledgements — 154
Bibliography — 154

7 Kallikrein-related Peptidases as Pharmaceutical Targets — 161
7.1 Introduction — 161
7.2 KLK disease markers as potential therapeutic targets — 162
7.3 KLKs in oncology — 165
7.3.1 Prostate cancer — 165
7.3.2 Ovarian and pancreatic cancer — 167
7.4 KLKs in inflammatory skin diseases — 169
7.4.1 Kallikrein expressions and activities in skin — 169
7.4.2 Netherton Syndrome as most relevant clinical model — 170
7.4.3 Atopic dermatitis, the potential major indication for kallikrein targeting — 171
7.4.4 Psoriasis and relevance of kallikreins — 172
7.4.5 Other potential skin disorders with kallikrein involvement — 172
7.5 KLKs in neurological disorders — 173
7.5.1 Alzheimer's disease and dementia — 173
7.5.2 Multiple sclerosis (MS) — 173

7.6 Kallikrein inhibitors to treat human diseases — 174
7.6.1 Design of KLK inhibitors and clinical development — 174
7.6.2 KLK inhibitors in oncology — 176
7.6.3 KLK inhibitors in dermatology — 179
7.7 Conclusions and Outlook — 180
Bibliography — 181

8 Expression of Kallikrein-related Peptidases under (Patho-)Physiological Conditions — 187
8.1 Introduction — 187
8.2 KLK expression in tissues and biological fluids under physiological conditions — 188
8.2.1 KLKs in the central and peripheral nervous system — 188
8.2.2 KLKs in the female reproductive system — 192
8.2.3 KLKs in the male reproductive system — 196
8.2.4 Cellular distribution of KLKs in the gastrointestinal system — 198
8.2.5 KLKs in the skin and skin appendages — 203
8.2.6 KLKs in the respiratory system — 207
8.2.7 KLKs in the urinary system — 207
8.2.8 KLKs in lymphatic and endocrine organs (adrenal glands, thyroid gland, parathyroid glands, pituitary gland) — 207
8.2.9 KLKs in the cardiovascular system — 211
8.2.10 KLKs in the skeletomuscular system — 211
8.3 Expression of KLKs in non-malignant diseases — 212
8.3.1 Non-malignant diseases of the CNS — 212
8.3.2 Inflammatory-related conditions — 215
8.4 Expression of KLKs in cancer tissues — 217
8.4.1 Cancers of the brain — 222
8.4.2 Cancers of the female reproductive system — 222
8.4.3 Cancers of the male reproductive system — 223
8.4.4 Cancers of the gastrointestinal system — 224
8.4.5 Cancers of the skin — 225
8.4.6 Lung cancer — 226
8.4.7 Cancers of the urinary system — 226
8.5 Conclusion — 227
Abbreviations — 227
Bibliography — 228

9 Kallikrein-related Peptidases within the Proteolytic Web — 251
9.1 Introduction — 251
9.2 KLKs as actors and targets during the initiation and amplification of extracellular proteolytic activity — 252

9.2.1 The KLK-dependent KLK activome — 252
9.2.2 Cross- and reciprocal activation of KLK and non-KLK proteases — 256
9.2.3 Inactivation of protease inhibitors — 260
9.3 KLKs in the termination of proteolytic activity — 260
9.3.1 Proteolytic inactivation of (non-)KLK proteases — 260
9.3.2 Processing of the uPA receptor — 261
9.3.3 Disarming of the proteinase-activated receptors — 262
9.4 Conclusion — 263
Bibliography — 264

10 Kallikrein-Kinin Cascade: Bioregulation by Human Tissue Kallikrein 1 (hK1, KLK1) — 271
10.1 Discovery of classical (true) tissue kallikrein and kinins — 271
10.2 Cellular localization — 272
10.3 Genomics and molecular structure — 273
10.4 Inhibitors of hK1 — 276
10.5 Modulation of membrane receptors — 277
10.6 Epigenetic regulation — 277
10.7 Kinin receptors and signaling — 278
10.7.1 Receptor subtypes — 278
10.7.2 Kinin receptor signaling — 279
10.7.3 Regulation of kinin receptor signaling — 280
10.8 Human disease — 281
10.8.1 Hypertension and renal damage — 281
10.8.2 Cardiac protection — 283
10.8.3 Inflammation and neutrophil function — 283
10.8.4 Cancer — 286
10.8.5 Angiogenesis — 286
10.9 Conclusion — 287
Abbreviations — 288
Bibliography — 289

11 Role of KLK4 in Dental Enamel Formation — 295
11.1 Introduction — 295
11.2 Early studies implicated proteases in dental enamel formation — 295
11.3 Investigations of enamel proteases discovered KLK4 — 296
11.4 *KLK4* and amelogenesis imperfecta — 297
11.5 *Klk4*$^{lacZ/lacZ}$ mice — 297
11.6 Other enamel specific genes — 302
11.7 Role of KLK4 in enamel formation — 304
11.8 Conclusion — 307
Bibliography — 307

12 Kallikrein-related Peptidases and Semen — 311
12.1 Introduction — 311
12.2 Expression pattern and origin of seminal KLKs — 312
12.3 Physiological function of seminal KLKs — 312
12.3.1 Seminal coagulation and fibrinolytic balance — 312
12.3.2 Sperm motility — 314
12.3.3 Reproductive immune interactions — 316
12.4 Proteolytic pathways of seminal KLKs — 318
12.4.1 Role of seminal zinc — 319
12.4.2 Role of seminal KLK inhibitors — 319
12.4.3 Other inhibitory mechanisms of seminal KLKs — 320
12.4.4 Seminal proteolytic activation cascade — 321
12.5 Conclusions and outlook — 322
Abbreviations — 323
Bibliography — 323

13 Kallikrein-related Peptidases and Inhibitors of the Skin — 329
13.1 Introduction — 329
13.2 KLKs in the epidermis — 331
13.3 Desquamation — 332
13.4 Regulation of protease activity — 333
13.4.1 KLK activation — 333
13.4.2 KLK inhibitors — 334
13.5 Skin disorders — 337
13.6 Conclusions and outlook — 340
Bibliography — 341

14 Physiological and Pathophysiological Roles of Kallikrein-related Peptidases in the Central Nervous System — 349
14.1 Introduction — 349
14.2 KLK expression and roles in CNS physiology — 349
14.2.1 KLK expression in the CNS — 349
14.2.2 Physiological roles of KLKs in the CNS — 353
14.2.3 Pathophysiological roles of KLKs in the CNS — 359
14.3 Conclusions and outlook — 363
Acknowledgements — 364
Abbreviation — 364
Bibliography — 364

15 Kallikrein-related Peptidases (KLKs), Proteinase-mediated Signaling and Proteinase-activated receptors (PARs) — 373
15.1 Proteinases: shock troops of the innate immune response — 373

15.2 Multiple mechanisms for proteinase-mediated signaling — 374
15.3 Proteinases and PAR-mediated signaling — 376
15.4 Linking PARs to the KLKs: the prostate connection — 378
15.5 Proteolytic cascades, KLKs and the innate immune response — 379
15.6 KLKs, other serine proteinases, PARs and inflammation — 379
15.7 KLKs, PARs and inflammation of the central nervous system and the skin — 380
15.8 KLKs, PARs and cancer — 382
15.9 KLKs and PARs: Therapeutic targets for inflammatory diseases, cancer and other disorders — 383
15.10 Blocking proteinase-mediated PAR activation: PAR-targeted blocking antibodies versus proteinase inhibitors — 387
15.11 Summary and outlook for the future — 389
Acknowledgements — 389
Bibliography — 390

Index — 399